What Patentex Oval N Treats: Main Uses and Benefits

Patentex Oval N is applied exclusively within the therapeutic domain of local family planning for managing the risk of unwanted pregnancy. The product is indicated for the prevention of pregnancy. This medication is commonly used within clinical settings that involve acute or disruptive patterns concerning conception risk, including cases where patients are seeking non-systemic contraceptive support or require a method for situational needs.

This ovule is used in contexts where concerns may become intense or disruptive, such as the anxiety of potential pregnancy. The therapeutic use involves situations marked by the risk of unwanted pregnancy and the preference for non-systemic management. This is relevant to scenarios requiring episodic use, which may assist with maintaining functional stability and supports the patient during episodes of heightened discomfort related to requirements of ongoing contraception. The non-systemic nature of the product may assist with managing concerns related to alternative therapeutic approaches.

“Providing a woman-controlled method available on-demand, this product supports patients in maintaining reproductive control.”

---

Quick Fact: Support for Non-Systemic Preference Patentex Oval N is considered relevant in contexts marked by increased discomfort or tension related to traditional systemic methods, contributing to easing the overall load related to alternative therapeutic approaches.

Regulatory References

1. NIH DailyMed drug label information

The official eligibility profile for Patentex Oval N (Nonoxinol-9) establishes limitations on its use based on physiological status and infectious disease risk, as mandated by government regulatory agencies.

---

Eligibility scope

Scope	Population Group/Statement
Populations for whom use is allowed	Adult women seeking contraception who have sex with only one partner who is not infected with HIV and has no other HIV risk factors
Populations for whom use is contraindicated	Patients who are pregnant; patients with known HIV/AIDS; or patients whose sex partner has known HIV/AIDS
Age-related eligibility rules	Established use is for adult women. Use in children and adolescents is not documented for this purpose.
Pregnancy and lactation eligibility	Pregnancy is an absolute contraindication. Use during lactation is restricted and requires medical consultation.

---

Eligibility classifications (high-level)

Classification	Description
Eligibility severity classification	Absolute Contraindication (HIV/AIDS status, Pregnancy)
Regulatory basis	FDA and equivalent required labeling for OTC vaginal spermicides
Eligibility-context constraints	Use is permitted only in low-risk sexual activity contexts.

---

Resulting eligibility structure

Official eligibility statements:

• Use is strictly prohibited for any patient who is pregnant or who is in a high-risk HIV context.
• Patients who do not know their own or their partner's HIV status are instructed to choose another form of birth control.
• Rectal use is also prohibited by regulation.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use the medicine almost entirely through absolute prohibitions tied to infectious risk and confirmed pregnancy status, limiting permitted use to a specifically low-risk adult population.

Interactions with Other Products and Substances

The official interaction profile for Patentex Oval N, based on regulatory documentation, is defined primarily by local pharmacodynamic conflicts and critical condition-based restrictions, consistent with its non-systemic mode of action.

• Local Vaginal Agents: Co-administration with other vaginal products, such as creams or suppositories intended for the treatment of yeast infections, may result in a pharmacodynamic interaction that compromises the product's contraceptive effectiveness. Concurrent local use is officially restricted.
• Material Compatibility: The product can cause certain barrier contraceptives to fail. It may weaken or break devices made of latex or polyurethane (including condoms, diaphragms, or cervical caps) that are not specifically labeled by the manufacturer as being compatible with nonoxynol-9.
• Procedural Timing Constraint: A mandatory timing rule applies to vaginal cleansing. Douching must be strictly avoided for a minimum of six hours following the last act of intercourse to ensure that the spermicidal action is completed.

Contraindicated Combination

Official regulatory labeling dictates a significant restriction related to a specific disease state: Patentex Oval N is formally contraindicated for use by an individual or their sexual partner who has Human Immunodeficiency Virus (HIV)/AIDS. This is a population-specific restriction documented because the product may increase the risk of getting HIV from an infected partner.

Consistent with its local administration, authoritative regulatory labels do not list any systemic pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters.

How Patentex Oval N Works

The mechanism of Patentex Oval N, derived from its single active ingredient, Nonoxinol-9 (N-9), is purely chemical and highly localized, involving the rapid, physical disruption of sperm cell structure at the site of application. The core function is achieved through two interrelated mechanistic domains.

---

Direct Chemical Lysis of Sperm Cell Membranes

Nonoxinol-9 functions as a nonionic surfactant, or detergent, targeting the lipid bilayer of the sperm cell plasma membrane—the primary biological target. The N-9 molecule physically inserts into this membrane, rapidly disrupting its integrity and increasing permeability. This direct lytic action leads to the immediate collapse of the cell's structure and the uncontrolled release of intracellular contents.

---

Irreversible Cellular Inactivation and Motility Cessation

The chemical destruction of the membrane and the disruption of osmotic homeostasis results in irreversible cellular inactivation. This mechanistic cascade simultaneously halts the metabolic processes necessary for progressive movement, specifically compromising the functionality of the flagellum and midpiece. The resulting physiological effect is the rapid and absolute immobilization and death of the sperm, which prevents them from achieving the cellular competency necessary for fertilization.

Patentex Oval N, which contains 100 mg of Nonoxinol-9, is designated for intravaginal administration only, consistent with its form as a vaginal suppository. The administration pattern is episodic and based on situational need, rather than a fixed daily schedule. The application involves the use of one single suppository unit prior to each intended act of sexual intercourse. This regimen characterizes products containing this spermicidal agent.

Proper use is dependent on specific timing for activation. The protocol involves inserting the suppository into the vagina at least 10 minutes before intercourse commences. This waiting period allows the unit to fully dissolve and activate its ingredients. The contraceptive action provided by a single unit is time-dependent and generally restricted to a duration of approximately one hour following insertion.

A crucial element of the usage protocol is the repetition requirement. If there are subsequent acts of intercourse, an additional, new suppository is applied prior to each separate act. This maintains application, as the effectiveness of the initial dose is not sustained. Furthermore, use is restricted to those after the onset of menstruation (menarche). If the user chooses to douche, a waiting period of at least six hours must elapse after the last act of intercourse to avoid interfering with the administration pattern.

Research Evidence / Overview of Studies for Patentex Oval N

Evidence for Local Chemical Contraception

Research has been conducted on the use of Nonoxinol-9 in exploring non-systemic options for contraception. Research focused on this indication includes Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate its application in local chemical contraception. These studies typically included healthy, sexually active women of reproductive age. The trials monitored key outcomes, such as the pregnancy rates observed within the groups using the product over defined time intervals, often up to 12 months.

Studies report that pregnancy rates, such as the number of pregnancies recorded per 100 women using the product, vary depending on whether usage was perfect (strictly following all directions) or typical (accounting for human errors in daily life). Findings indicate that research examining this product contributes to the broader evidence landscape for non-hormonal, on-demand methods.

Investigation into Prevention of Other Conditions (STI/HIV Research)

Nonoxinol-9 was evaluated in numerous large-scale Randomized Controlled Trials and Systematic Reviews to determine if it could also provide protection against sexually transmitted infections (STIs), including HIV. The data show patterns related to these outcomes that are highly consistent: findings indicate that research did not support the use of Nonoxinol-9 as a barrier or chemical preventative for HIV or other STIs. In fact, research describes that in some high-risk study groups, frequent use was observed in some studies to be associated with the observation of genital lesions.

Unanswered Questions and Research Gaps

Despite the available evidence, certainty remains low in several areas. Long-term effects are not fully established, as the evidence describing the use of the ovule mainly comes from trials with follow-up durations that were limited, typically lasting for less than one year. Data for certain groups remain limited, including adolescents and older adults. Research continues to explore user adherence and the acceptability of the product when applied in observational settings.

Common questions about Patentex Oval N (FAQ)

---

Q: How long after using Patentex Oval N can I have sexual intercourse?

According to the official product information, the preparation must be allowed enough time to dissolve completely. Regulatory guidelines specify a waiting period of at least 10 minutes after insertion before sexual intercourse to allow the product to take effect. The official documentation indicates that if intercourse is delayed beyond one hour, a new ovule should be inserted.

---

Q: What happens if I or my partner use a product containing vaseline (petroleum jelly) while using Patentex Oval N?

Official information indicates that products containing vaseline, oils, or other fatty substances can negatively affect the effectiveness of the ovule. Regulatory documents advise against using these substances in conjunction with Patentex Oval N. For this reason, any concomitant product, such as a lubricant, is recommended by the label to be confirmed as oil- or fat-free.

---

Q: Does using Patentex Oval N affect the natural acidity (pH level) of the vagina?

Studies and official information state that Patentex Oval N does not significantly alter the normal pH level in the vagina. The label notes that maintaining the natural acidity is generally recognized as important for vaginal balance. Should any irritation or imbalance be experienced, the official documentation advises consulting a healthcare professional.

---

Q: Can I use Patentex Oval N as the only method of contraception?

According to the regulatory documents, Patentex Oval N is a spermicidal product intended for use as a local contraceptive. Its effectiveness depends heavily on correct and consistent use. Patients who have questions about its effectiveness or suitability for their situation should seek consultation with a healthcare professional.

---

Q: What is the active ingredient in Patentex Oval N and how does it work?

The active ingredient in Patentex Oval N is benzalkonium chloride. This substance is classified as a spermicide, which are chemical agents intended to immobilize or kill sperm. Official information states that the drug works locally within the vagina to provide a barrier and spermicidal effect before intercourse.

---

Q: What should I do if the ovule is very soft or melts before I can insert it?

Official product documentation notes that if the ovules have become very soft due to high ambient temperature, the product label suggests briefly cooling them. Official documentation suggests placing the ovule packaging in a cool place, such as a refrigerator, before use. This action helps to firm up the ovule, making correct insertion easier.

---

Q: Is it required to insert a new ovule for every instance of sexual intercourse?

Yes, official instructions specify that a new ovule must be inserted for every instance of sexual intercourse. This is essential to ensure that a full and effective dose of the active ingredient is present for each act. The regulatory documents highlight that adherence to the application guidelines is essential for the product's contraceptive efficacy.

---

Q: How soon after insertion is the ovule effective?

The official product information states that the ovule must be completely dissolved before it can take effect. This requires a waiting period of at least 10 minutes after insertion. Observing this minimum wait time is necessary for the product to achieve its intended contraceptive effect.

The official regulatory guidelines define specific conditions for storing and disposing of Patentex Oval N vaginal suppositories.

Official Storage Conditions

The product must be stored at controlled room temperature, specifically between 15 C and 30 C (58 F and 86 F). Storage requirements strictly prohibit freezing and storing the product above 30 C. To maintain product stability, it must be stored in the original package to ensure protection from both light and moisture. As a mandatory rule, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Patentex Oval N must be properly discarded according to local pharmaceutical waste regulations. Regulatory guidance instructs against flushing the medicine down the toilet or pouring it into a drain. Patients are advised to consult their pharmacist or local waste disposal service for guidance on safe discarding procedures.